Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways
An HIV-1 vaccine continues to be a major target to halt the AIDS pandemic. The limited efficacy of the RV144 phase III clinical trial with the canarypox virus-based vector ALVAC and a gp120 protein component led to the conclusion that improved immune responses to HIV antigens are needed for a more e...
Spremljeno u:
| Glavni autori: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI AG
2017-12-01
|
| Serija: | Viruses |
| Teme: | |
| Online pristup: | https://www.mdpi.com/1999-4915/10/1/7 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|